The market for anti-dyskinesia agents is experiencing significant growth driven by rising prevalence of drug-induced movement disorders and expanding therapeutic pipelines. Here's an analysis of key dynamics:
Market Growth and Drivers
The global tardive dyskinesia (TD) therapeutics market is projected to reach $5.88 billion by 2035, growing at 4.8% CAGR from $3.51 billion in 2024[14]. Key factors include:
- 20-30% of long-term antipsychotic users developing TD[6][16]
- Expanding use of neuroleptics for schizophrenia, bipolar disorder, and gastrointestinal conditions[6][8]
- Dominance of VMAT2 inhibitors (valbenazine and deutetrabenazine) capturing $1.6 billion in 2023[6]
Neurocrine Biosciences leads with INGREZZA® (valbenazine), achieving 96.13% U.S. market share in 2022 through strong sales and strategic approvals[1]. Teva Pharmaceuticals follows with Austedo® (deutetrabenazine), growing steadily since its 2017 FDA approval[1].
Patent Landscape and Innovation
Recent developments highlight competitive IP strategies:
- Vistagen secured Canadian (2034 expiry) and U.S. patents for AV-101, an NMDAR antagonist showing 64% dyskinesia reduction in trials[4][12]
- Amarantus extended protection for eltoprazine (5HT1A/1B agonist) through 2027 via continuation patents[2]
- Riluzole patents cover both Parkinson's LID and antipsychotic-induced TD[7]
- Reformulation patents like ADS-5102 (extended-release amantadine) address dosing challenges in LID[13]
Emerging pipeline candidates include:
- DYSVAL® (Mitsubishi Tanabe Pharma) targeting Asian markets[1]
- SOM Biotech and Luye Pharma developing novel VMAT2 inhibitors[1]
- mGluR5 NAMs (e.g., AFQ056) showing 40% LID reduction in trials[12]
Regional Dynamics
North America dominates (44.2% share) due to:
- High antipsychotic prescription rates affecting 600,000+ Americans[6][10]
- Advanced diagnostics and insurance coverage for TD therapies[14]
Europe and Asia-Pacific show growth potential through:
- Germany's projected 7.4% CAGR in hospital pharmacy distribution[6]
- Mitsubishi Tanabe's planned DYSVAL® approvals in Japan/Korea[1]
Challenges and Opportunities
Key barriers include:
- 30% remission rates after neuroleptic discontinuation[10]
- Limited awareness in developing regions[1][6]
Growth frontiers involve:
- Digital health platforms improving medication adherence[14]
- Combination therapies targeting serotonin and glutamate pathways[5][12]
- Orphan drug designations accelerating development timelines[2][4]
"The pipeline candidates of these companies will occupy a significant proportion of the market in the future" [1], highlighting the sector's innovation trajectory.
This evolving landscape combines established VMAT2 inhibitors with novel mechanisms (NMDAR/glycine site antagonism, 5HT modulation) to address unmet needs in both TD and LID markets.
References
- https://www.fortunebusinessinsights.com/tardive-dyskinesia-therapeutics-market-107532
- https://parkinsonsnewstoday.com/news/amarantus-gets-us-patent-covering-method-of-treating-parkinsons-disease-levodopa-induced-dyskinesia/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6491120/
- https://www.businesswire.com/news/home/20230713041093/en/Vistagen-Receives-Notice-of-Allowance-for-AV-101-Canadian-Patent-for-Treatment-of-Dyskinesia-Related-to-Levodopa-Therapy-for-Parkinsons-Disease
- https://pubmed.ncbi.nlm.nih.gov/31694421/
- https://www.gminsights.com/industry-analysis/tardive-dyskinesia-therapeutics-market
- https://patents.google.com/patent/AU1780699A/en
- https://www.drugwatch.com/reglan/
- https://pubmed.ncbi.nlm.nih.gov/24310603/
- https://www.coherentmarketinsights.com/market-insight/tardive-dyskinesia-drugs-market-218/market-size-and-trends
- https://meshb-prev.nlm.nih.gov/record/ui?ui=D018726
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4540734/
- https://www.openaccessjournals.com/articles/amantadine-and-phenytoin-patent-protected-cases-of-drug-repositioning.html
- https://www.metatechinsights.com/industry-insights/tardive-dyskinesia-therapeutics-market-2026
- https://www.maxval.com/blog/pharma-patent-landscape-parkinsons-disease-uncovered/
- https://www.mordorintelligence.com/industry-reports/tardive-dyskinesia-treatment-market
